POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Phase Two clinical trials of COVID-globulin launched in Russia

Christian Fernsby |
Phase Two clinical trials of the COVID-globulin preparation created on the basis of blood of coronavirus patients have been launched in Moscow with 156 patients participating, the press service of the capital’s Healthcare Department reported.

Article continues below




"In Moscow, Phase Two clinical trials of the unique COVID-globulin preparation begin. The day after the preparation was registered, a permit for clinical trials was obtained.

"In all, six Moscow hospitals which work with coronavirus patients will participate in this endeavor. It is planned to conduct the second phase together with Rostec and Nacimbio over 2-3 months; 156 COVID-19 patients will participate in it with their informed consent," the press service said.

It was noted that Phase Two placebo-controlled trials involved a study of the preparation’s efficacy and safety. The trials will be conducted in compliance with international standards.

Moscow will become the first city in Russia to use a specific immunoglobulin against the coronavirus infection. The COVID-globulin preparation is based on blood plasma of people who have already had the coronavirus and contains antibodies to it.

An administration of the preparation helps prevent a severe course of the disease and assists the human body in fighting the infection while a natural immunity is formed.

In order to develop the preparation, the city provided 2.5 tonnes of donor plasma as well as prepared medical centers for Phase Two and Three clinical trials. Moscow medics actively researched the use of donor plasma of coronavirus patients for the production of immunoglobulin.

"Moscow has been stocking up on plasma of the coronavirus patients for over a year already. The main goal of procuring it was transfusion of such plasma to inpatients with moderate and severe forms of the disease. After over a year of its usage the transfusion method has proved its effectiveness - in more than half of the cases after the transfusion the patients were spared the necessity to be switched to an artificial respiratory support with the use of lung ventilators," TASS cited the press service aas saying.


What to read next

Johnson & Johnson says its single-dose COVID-19 vaccine is 66% effective
Casirivimab and imdevimab reduced hospitalisation, death by 70% in non-hospitalised patients with COVID-19
Moderna begins testing next-generation coronavirus vaccine